Jane Street Group LLC Reduces Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Jane Street Group LLC cut its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 6.8% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 161,193 shares of the company’s stock after selling 11,796 shares during the quarter. Jane Street Group LLC’s holdings in Zentalis Pharmaceuticals were worth $593,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ZNTL. Erste Asset Management GmbH purchased a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth approximately $37,000. Paloma Partners Management Co bought a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at approximately $37,000. Aigen Investment Management LP bought a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at approximately $41,000. Capstone Investment Advisors LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at approximately $48,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Zentalis Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock valued at $50,000 after acquiring an additional 5,333 shares during the last quarter.

Analysts Set New Price Targets

ZNTL has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Finally, Guggenheim lowered their price objective on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.00.

Zentalis Pharmaceuticals Price Performance

Shares of ZNTL stock opened at $3.24 on Friday. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $2.66 and a fifty-two week high of $18.07. The stock’s 50-day moving average is $3.33 and its two-hundred day moving average is $3.50. The firm has a market cap of $230.90 million, a P/E ratio of -1.30 and a beta of 1.84.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.36. As a group, research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.48 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.